Home › Compare › FEIOF vs ABBV
FEIOF yields 9.51% · ABBV yields 3.12%● Live data
📍 ABBV pulled ahead of the other in Year 3
Combined, FEIOF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FEIOF + ABBV for your $10,000?
Feintool International Holding AG, together with its subsidiaries, provides fineblanked, formed steel components, and punched electro sheet metal products in Switzerland, rest of Europe, Germany, the United States, Japan, and China. It operates through two segments, System Parts and Fineblanking Technology. The System Parts segment develops, produces, and sells high-precision system components and assemblies using fineblanking and forming technology, as well as electronic sheet stamping; and sells production-specific tools to third-party customers. The Fineblanking Technology segment engages in the development, manufacture, and sale of presses, tools, peripheral systems, and various related services. It provides its products for use in automobile industry, such as engine, chassis, transmission, safety systems, peripheral drives, and seat mechanisms applications, as well as for application in mechanical engineering, power generation, electric motors and drives, tools and household, and medical technology. The company was founded in 1959 and is headquartered in Lyss, Switzerland. Feintool International Holding AG is a subsidiary of Artemis Beteiligungen I AG.
Full FEIOF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.